The abstract notes that combined treatment results in long-term survival for 'some patients' with IDH-mutant tumors, but doesn't explain what distinguishes these exceptional responders. Understanding these mechanisms could identify biomarkers for prognosis and guide personalized treatment strategies. Gap type: unexplained_observation Source paper: Primary brain tumours in adults. (None, None, PMID:37738997)
Landscape Summary: Why do some IDH-mutant glioma patients achieve long-term survival (>10-20 years) while others do not? is a 0.8 priority gap in neuro-oncology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why do some IDH-mutant glioma patients achieve long-term survival (>10-20 years) while others do not? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: